Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS
- PMID: 12557297
- DOI: 10.1002/ana.10476
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS
Abstract
The known neuroprotective effects of minocycline and creatine in animal models of amyotrophic lateral sclerosis (ALS) led us to examine whether the combination of these agents would result in increased neuroprotection. As previously reported, we confirmed in ALS mice that either minocycline or creatine treatment results in improvement in motor performance and extended survival. We report that combination of minocycline and creatine resulted in additive neuroprotection, suggesting this to be a novel potential strategy for the treatment of ALS. To our knowledge, this is the first report demonstrating additive neuroprotection of a combinatorial approach in a mouse model of ALS. Adding relevancy to our findings, minocycline and creatine, are relatively safe, cross the blood-brain barrier, and are currently available for human evaluation.
Comment in
-
Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials.Ann Neurol. 2003 Apr;53(4):423-6. doi: 10.1002/ana.10561. Ann Neurol. 2003. PMID: 12666108 Review. No abstract available.
Similar articles
-
Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.Ann Neurol. 2003 Apr;53(4):429-36. doi: 10.1002/ana.10500. Ann Neurol. 2003. PMID: 12666110
-
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.J Neurochem. 2004 Feb;88(3):576-82. doi: 10.1046/j.1471-4159.2003.02160.x. J Neurochem. 2004. PMID: 14720207
-
Minocycline delays disease onset and mortality in a transgenic model of ALS.Neuroreport. 2002 Jun 12;13(8):1067-70. doi: 10.1097/00001756-200206120-00018. Neuroreport. 2002. PMID: 12060810
-
Lost in translation: treatment trials in the SOD1 mouse and in human ALS.Neurobiol Dis. 2007 Apr;26(1):1-13. doi: 10.1016/j.nbd.2006.12.015. Epub 2007 Jan 3. Neurobiol Dis. 2007. PMID: 17300945 Review.
-
Molecular targets for neuroprotection.Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:14-8. doi: 10.1080/1734470410019780. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004. PMID: 15512862 Review.
Cited by
-
Brain-inhabiting bacteria and neurodegenerative diseases: the "brain microbiome" theory.Front Aging Neurosci. 2023 Oct 19;15:1240945. doi: 10.3389/fnagi.2023.1240945. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37927338 Free PMC article. Review.
-
Therapeutic targeting of ALS pathways: Refocusing an incomplete picture.Ann Clin Transl Neurol. 2023 Nov;10(11):1948-1971. doi: 10.1002/acn3.51887. Epub 2023 Aug 28. Ann Clin Transl Neurol. 2023. PMID: 37641443 Free PMC article. Review.
-
Neurodegeneration, Mitochondria, and Antibiotics.Metabolites. 2023 Mar 12;13(3):416. doi: 10.3390/metabo13030416. Metabolites. 2023. PMID: 36984858 Free PMC article. Review.
-
Sepsis-Associated Encephalopathy: A Mini-Review of Inflammation in the Brain and Body.Front Aging Neurosci. 2022 May 27;14:912866. doi: 10.3389/fnagi.2022.912866. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35711904 Free PMC article. Review.
-
Blocking glutamate mGlu5 receptors with the negative allosteric modulator CTEP improves disease course in SOD1G93A mouse model of amyotrophic lateral sclerosis.Br J Pharmacol. 2021 Sep;178(18):3747-3764. doi: 10.1111/bph.15515. Epub 2021 Jun 29. Br J Pharmacol. 2021. PMID: 33931856 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
